Dr. Nusayba A. Bagegni, MD
Medical Oncology (Medical Oncology Physician)
1 Barnes Jewish Hospital Plz, Div Im Medical Oncology
Saint Louis, MO 63110
- Medicare participating
At a glance
- Years since graduation
- 16
- In the NPI registry since
- 2010
- Medicare patients seen, 2024
- 226
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
MO license 2013020285
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Barnes Jewish Hospital Saint Louis, MO
- Missouri Baptist Medical Center Saint Louis, MO
- Barnes-Jewish West County Hospital Creve Coeur, MO
- Memorial Hospital Belleville, IL
Medical groups
- Washington University (3,029 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 226
- Services billed
- 19,844
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Injection, fosaprepitant, 1 mg | 2,700 | 12 |
| Injection, denosumab, 1 mg | 2,520 | 14 |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 1,360 | 11 |
| Injection, dexamethasone sodium phosphate, 1 mg | 870 | 41 |
| Injection, palonosetron hcl, 25 mcg | 510 | 29 |
| Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 312 | 14 |
| Injection, granisetron hydrochloride, 100 mcg | 190 | 12 |
| Injection of additional new drug or substance into vein | 160 | 49 |
| Insertion of needle into vein for collection of blood sample | 147 | 71 |
| Administration of chemotherapy into vein, 1 hour or less | 141 | 67 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in Saint Louis, MO | 357 |
| Letrozole Other prescribers in Saint Louis, MO | 191 |
| Ibrance (palbociclib) | 115 |
| Tamoxifen Citrate Other prescribers in Saint Louis, MO | 80 |
| Eliquis (apixaban) Other prescribers in Saint Louis, MO | 51 |
| Exemestane | 46 |
| Ondansetron Hcl Other prescribers in Saint Louis, MO | 41 |
| Dexamethasone Other prescribers in Saint Louis, MO | 40 |
| Gabapentin Other prescribers in Saint Louis, MO | 35 |
| Prochlorperazine Maleate Other prescribers in Saint Louis, MO | 23 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $417,821 in research payments for these studies, mostly to the institutions running them.
- A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd
Janssen Research & Development, LLC - A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator Choice Chemotherapy in HER2-low, Hormone Receptor Positive Breast Cancer Patients whose Disease has Progresse…
AstraZeneca Pharmaceuticals LP - A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer
Daiichi Sankyo Inc. · Completed · NCT04699630 - A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual…
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.